Filed by Johnson & Johnson pursuant to Rule 425 promulgated
under the Securities Act of 1933, as amended, and deemed
filed pursuant to Rule 14a-12 promulgated under the
Securities Act of 1934, as amended.

Subject Company:  Closure Medical Corporation
Commission File No.:  000-28748



     
Q.   Please comment on the timing of the Closure
     transaction.

A.   All inquires should be directed to Closure Medical at
     www.closuremed.com, with the exception of the Hart-Scott
     Rodino filings that have been completed by both Johnson &
     Johnson and Closure Medical.

     
                                   ESTIMATED DATE
STATUS
     
Hart-Scott-Rodino Filing           1Q'05             Filed


     



     

This material is not a substitute for the proxy statement
CLOSURE Medical will file with the Securities and Exchange
Commission. Investors are urged to read the proxy statement,
including detailed risk factors, when it becomes available,
because it will contain important information. The proxy
statement and other documents, which will be filed by
CLOSURE Medical with the Securities and Exchange Commission,
will be available free of charge at the SEC's website,
www.sec.gov, or by visiting CLOSURE Medical's website at
www.closuremed.com or the "Clients" section of the Allen &
Caron website at www.allencaron.com.

CLOSURE Medical Corporation and certain of its directors,
executive officers and certain other members of its
management may be deemed to be soliciting proxies from
CLOSURE Medical's shareholders in connection with the
proposed transaction. Investors may obtain a detailed list
of names, affiliations and interests of CLOSURE Medical
participants in the solicitation of proxies of CLOSURE
Medical's shareholders by reading the proxy statement when
it becomes available.